Oppenheimer raised the firm’s price target on Perspective Therapeutics to $1.50 from $1.20 and keeps an Outperform rating on the shares following quarterly results. Details on Perspective’s pipeline and plans were provided last week during an analyst day in NYC, the firm also notes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
- Perspective Therapeutics sees cash runway into 2026
- Perspective Therapeutics reports 2023 EPS (17c) vs. (8c) last year
- Perspective Therapeutics to host analyst day
- Perspective Therapeutics announces collaboration agreement with Bristol Myers
